Raffi Asadorian
2023 - AcelRx Pharmaceuticals
In 2023, Raffi Asadorian earned a total compensation of $742.6K as Chief Financial Officer at AcelRx Pharmaceuticals, a 2% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $181,394 |
|---|---|
| Option Awards | $49,007 |
| Salary | $488,668 |
| Stock Awards | $10,340 |
| Other | $13,200 |
| Total | $742,609 |
Asadorian received $488.7K in salary, accounting for 66% of the total pay in 2023.
Asadorian also received $181.4K in non-equity incentive plan, $49K in option awards, $10.3K in stock awards and $13.2K in other compensation.
Rankings
In 2023, Raffi Asadorian's compensation ranked 1,534th out of 2,983 executives tracked by ExecPay. In other words, Asadorian earned more than 48.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,534 out of 2,983 | 49th |
Division Manufacturing | 898 out of 1,637 | 45th |
Major group Chemicals And Allied Products | 580 out of 906 | 36th |
Industry group Drugs | 564 out of 869 | 35th |
Industry Pharmaceutical Preparations | 399 out of 627 | 36th |
Source: SEC filing on April 29, 2024.
Asadorian's colleagues
We found two more compensation records of executives who worked with Raffi Asadorian at AcelRx Pharmaceuticals in 2023.
News
AcelRx Pharmaceuticals CEO Vincent Angotti's 2023 pay slips 7% to $1.2M
April 29, 2024
AcelRx Pharmaceuticals CEO Vincent Angotti's 2022 pay falls 47% to $1.3M
August 28, 2023
AcelRx Pharmaceuticals CEO Vincent Angotti's 2021 pay jumps 39% to $2.4M
June 3, 2022
AcelRx Pharmaceuticals CEO Vincent Angotti's 2019 pay jumps 22% to $2.1M
April 24, 2020
AcelRx Pharmaceuticals CEO Vincent Angotti's 2018 pay falls 26% to $1.7M
May 14, 2019